UroGen Pharma (URGN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.28
- Estimate
- -$0.26
- Surprise
- -5.7%
- Revenue (period 2026-06-30)
- $72.5M
- Score at report (before → after)
- 5.7 → 5.8/10
Revenue source: xbrl.
How the report landed
UroGen Pharma (URGN) reported a wider loss than forecast — diluted EPS of -$0.28 against the -$0.26 estimate (a 5.7% shortfall). TrendMatrix's engine moved from Hold (5.7/10) to Buy (Wait) at 5.8/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates URGN Sell at 6.0/10.
1 of the last 4 quarters beat the estimate; this quarter's -5.7% surprise compares with a -1.9% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Product: Jelmyto and Zusduri
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7)
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $44.00
- Price target
- $52.20
- Stop
- $40.45
- Upside to target
- +18.6%
- Reward-to-risk
- 2.0:1
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
URGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.04B
- P/E (fwd)
- 14.9
- 52-week range
- $15.86–$50.81
- Off 52-week high
- 13.4%
- RSI (14)
- 40
- Volume vs avg
- 1.24×
- Score today
- 6.0/10